Books > Medicine > Other branches of medicine > Pharmacology
|
Buy Now
Monoamine Oxidase Inhibitors - Clinical Pharmacology, Benefits, & Potential Health Risks (Hardcover)
Loot Price: R5,642
Discovery Miles 56 420
You Save: R602
(10%)
|
|
Monoamine Oxidase Inhibitors - Clinical Pharmacology, Benefits, & Potential Health Risks (Hardcover)
Expected to ship within 12 - 17 working days
|
Donate to Against Period Poverty
Total price: R5,662
Discovery Miles: 56 620
|
This book provides basic and applied knowledge about monoamine
oxidase inhibitors (MAOIs), their classification, and clinical
application as neuroprotective agents and will be a valuable source
of new knowledge for doctors, patients, medical students, teachers,
researchers, and basic biomedical scientists interested in learning
the appropriate clinical application of MAOIs without any
misunderstanding for the prevention and/or treatment of
neurological and neuropsychiatric disorders. The book will be of
immediate interest to patients suffering from Parkinson's disease
(PD), Alzheimer's disease (AD), post-traumatic stress disorders
(PTSD), panic disorders, attention deficit hyperactivity disorders
(ADHD), and major depression. Physicians interested in learning
more about MAOIs and their molecular and pharmacological mechanism
of action will highly benefit from the book's
clinically-interesting contents. In general, this book will be a
valuable source of knowledge for the basic researcher, clinically
useful for the physician, and therapeutically-beneficial for the
patients. The book can also serve as a guide for Masters and Ph.D
students interested in conducting research on MAOIs. Particularly,
MD doctors, students, and professors will find this book
interesting to enhance their basic knowledge about MAOIs and their
potential benefits and adverse effects for the better clinical
management of drug-resistant PD, AD, and MDDs. Furthermore, recent
knowledge regarding the molecular mechanism of MAOIs-mediated
protection at the cellular, molecular, and genetic level is
thought-provoking and motivates the young scientists to augment
research on developing novel drugs with minimum or no adverse
effects. It is envisaged that future research on specific
CB-targeted MAOIs will have superior pharmacogenomics profiles,
enhanced margin of safety, maximum therapeutic index, and minimum
or no adverse effects.'
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|